CD86 Mouse anti-Human, FITC, Clone: BU63, Invitrogen
Mouse Monoclonal Antibody
Manufacturer: Invitrogen MHCD8601
Commonly used, FITC conjugates provide relatively high absorptivity, excellent fluorescence quantum yield, and good water solubility.CD86 is one of two ligands (the other CD80) for CTLA4 and CD28. CD86 acts as costimulatory molecule in eliciting T-cell help during antigen presentation. Antigen presentation in the absence of sufficient co-stimulation involving CD86/CD80 can induce tolerance. CD80 appears to play a role distinct from CD80 in T helper cell differentiation. CD86 is a type I membrane protein that is a member of the immunoglobulin superfamily. The CD86 protein is expressed by antigen-presenting cells, and it is the ligand for two proteins at the cell surface of T cells, CD28 antigen and cytotoxic T-lymphocyte-associated protein 4. Binding of CD86 with CD28 antigen is a costimulatory signal for activation of the T-cell. Binding of CD86 with cytotoxic T-lymphocyte-associated protein 4 negatively regulates T-cell activation and diminishes the immune response. Alternative splicing results in two transcript variants encoding different isoforms of CD86. Additional transcript variants have been described for CD86, but their full-length sequences have not been determined. Diseases associated with CD86 dysfunction include gallbladder squamous cell carcinoma and myocarditis.
|B-lymphoblastoid cell line ARH 77|
|PBS with 4mg/mL BSA and 0.1% sodium azide|
|B7-2, B7.2, B70, CD28LG2, LAB72, MGC34413, B-lymphocyte activation antigen B7-2, B-lymphocyte antigen B7-2, B7-2 antigen, BU63, CD28 antigen ligand 2|
|4° C, store in dark|
The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok